BTK and B-cell chronic lymphocytic leukemia: The aim of this study was to evaluate whether inhibiting GluCer production by targeting UGCG, both pharmacologically and genetically, could impact leukemic cells survival, and in combination with ibrutinib targeting Bruton tyrosine kinase (BTK) used in the first-line setting for CLL.